Evidence map›Paper›PMID 30483600›Full record

ArticleWellcome open research2018

ICR142 Benchmarker: evaluating, optimising and benchmarking variant calling performance using the ICR142 NGS validation series.

Elise Ruark, Esty Holt, Anthony Renwick, Márton Münz, Matthew Wakeling, Sian Ellard, Shazia Mahamdallie, Shawn Yost, Nazneen Rahman

Abstract read
In one paragraph

Article in Wellcome open research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elise RuarkDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.ORCID https://orcid.org/0000-0002-9373-4059
Esty HoltDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.ORCID https://orcid.org/0000-0003-2436-7811
Anthony RenwickDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.
Márton MünzDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.
Matthew WakelingInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, EX2 5DW, UK.ORCID https://orcid.org/0000-0002-6542-9241
Sian EllardInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, EX2 5DW, UK.ORCID https://orcid.org/0000-0002-7620-5526
Shazia MahamdallieDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.
Shawn YostDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.
Nazneen RahmanDivision of Genetics & Epidemiology, The Institute of Cancer Research, London, SM2 5NG, UK.ORCID https://orcid.org/0000-0003-4376-0440

Funding

Wellcome Trust
6 · The paper itself

Abstract

Evaluating, optimising and benchmarking of next generation sequencing (NGS) variant calling performance are essential requirements for clinical, commercial and academic NGS pipelines. Such assessments should be performed in a consistent, transparent and reproducible fashion, using independently, orthogonally generated data. Here we present ICR142 Benchmarker, a tool to generate outputs for assessing germline base substitution and indel calling performance using the ICR142 NGS validation series, a dataset of Illumina platform-based exome sequence data from 142 samples together with Sanger sequence data at 704 sites. ICR142 Benchmarker provides summary and detailed information on the sensitivity, specificity and false detection rates of variant callers. ICR142 Benchmarker also automatically generates a single page report highlighting key performance metrics and how performance compares to widely-used open-source tools. We used ICR142 Benchmarker with VCF files outputted by GATK, OpEx and DeepVariant to create a benchmark for variant calling performance. This evaluation revealed pipeline-specific differences and shared challenges in variant calling, for example in detecting indels in short repeating sequence motifs. We next used ICR142 Benchmarker to perform regression testing with DeepVariant versions 0.5.2 and 0.6.1. This showed that v0.6.1 improves variant calling performance, but there was evidence of minor changes in indel calling behaviour that may benefit from attention. The data also allowed us to evaluate filters to optimise DeepVariant calling, and we recommend using 30 as the QUAL threshold for base substitution calls when using DeepVariant v0.6.1. Finally, we used ICR142 Benchmarker with VCF files from two commercial variant calling providers to facilitate optimisation of their in-house pipelines and to provide transparent benchmarking of their performance. ICR142 Benchmarker consistently and transparently analyses variant calling performance based on the ICR142 NGS validation series, using the standard VCF input and outputting informative metrics to enable user understanding of pipeline performance. ICR142 Benchmarker is freely available at https://github.com/RahmanTeamDevelopment/ICR142_Benchmarker/releases.

Indexed as

benchmarkingDeepVariantfalse detection rateGATKnext generation sequencingOpExsensitivityspecificityVariant calling

Identifiers

PMID30483600
PMCPMC6234721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.